<?xml version="1.0" encoding="UTF-8"?>
<p>Breast cancer is a very common cancer type all over the world, and despite of its possible early detection by advanced diagnostic techniques, breast cancer is still considered the leading cause of death among women worldwide
 <xref rid="CIT0016" ref-type="bibr">
  <sup>16–17</sup>
 </xref>. Thus, there is a serious continuous demand for the discovery of more effective anti-breast cancer agents. Several studies reported the overexpression of several PKs in primary as well as in metastatic breast cancers such as vascular endothelial growth factor receptor (VEGFR)
 <xref rid="CIT0018" ref-type="bibr">
  <sup>18–20</sup>
 </xref>, fibroblast growth factor receptor (FGFR)
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20–21</sup>
 </xref>, platelet-derived growth factor receptor (PDGFR)
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0022" ref-type="bibr">
  <sup>22</sup>
 </xref>, cyclin dependent kinases (CDKs) and their activating cyclins
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23–27</sup>
 </xref>, and glycogen synthase kinase 3β (GSK-3β)
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28–30</sup>
 </xref> and references therein.
</p>
